OxySure Therapeutics (OXYS) Appoints Territory Sales Manager in South Florida
Frisco, Texas, January 28, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its “oxygen from powder” technology and other innovative emergency medical solutions today announced that Edward C. Diaz was appointed to the position of Territory Sales Manager in South Florida.
“We are pleased to welcome Eddy to our growing national sales team and look forward to developing a solid base in South Florida,” stated Julian T. Ross, CEO of OxySure. “The Florida market is tremendous and largely untapped, and with Eddy on board we are confident of an immediate and significant sales impact,” Ross added.
Eddy Diaz brings over 20 years of experience to OxySure in both business development and sales management in the manufacturing and government sectors. He has worked with several industrial and safety organizations, including T.A.P.E Incorporated, Grainger, Lehigh Safety Company and 3M calling on the medical, aviation, marine and industrial markets. “We are excited to add Mr. Diaz to our current sales team and look forward to his contributions in the Florida market,” stated Clark Hood, Vice-President of Worldwide Sales for OxySure. “He has managed multi-million dollar territories and consistently exceeded his sales quotas. He is also bilingual and brings a tremendous amount of expertise in the Caribbean market, which will be an area of growth for OxySure in 2016,” Hood added. Mr. Diaz attended Miami Dade Jr. College and Florida International University.
At OxySure, Mr. Diaz will focus on developing new resuscitation business within the municipal, government, corporate, public access and school markets, while also supporting and expanding our existing distribution partnerships. He is based in West Palm Beach and will be responsible for South Florida and portions of the Caribbean Region.
About OxySure Therapeutics, Inc.
OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com
Contact:
Redchip Companies, Inc.
Jon Cunningham: jon@redchip.com
800-733-2447, ext. 107
Forward-Looking Statements
Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014.
Tags: